Navigation Links
Bayer Schering Exercises Option to Develop Solid Tumor BiTE Antibody with Micromet
Date:12/1/2009

statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. These forward-looking statements include statements regarding the operation of the global collaboration with Bayer Schering Pharma, the efficacy, safety and intended utilization of our product candidates, including the BiTE antibody that is the subject of the agreement with Bayer Schering Pharma, the mode of action of BiTE antibodies, the conduct, timing and results of future clinical trials, expectations of the future expansion of our product pipeline and collaborations, and the future payment of milestone and royalty payments by Bayer Schering Pharma. You are urged to consider statements that include the words "ongoing," "may," "will," "believes," "potential," "expects," "plans," "anticipates," "intends," or the negative of those words or other similar words to be uncertain and forward-looking. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward-looking statements include the risk that product candidates that appeared promising in early research, preclinical studies or clinical trials do not demonstrate safety and/or efficacy in subsequent clinical trials, the risk that encouraging results from early research, preclinical studies or clinical trials may not be confirmed upon further analysis of the detailed results of such research, preclinical study or clinical trial, the risk that additional information relating to the safety, efficacy or tolerability of our product candidates may be discovered upon further analysis of preclinical or clinical trial data, the risk that we or our collaborators will not obtain approval to market our product candidates, the risks associated with reliance on outside financing to meet capital requirements, and the risks associated with reliance on collaborat
'/>"/>
SOURCE Micromet, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Simmons Firms Partner Trent Miracle Chosen to Help Lead National Litigation Against Bayer
2. Bayer HealthCare Pharmaceuticals Initiates Phase III Trial with Florbetaben PET Tracer for Imaging of Cerebral beta-Amyloid Plaques, a Pathological Hallmark of Alzheimers Disease
3. Bayer Consumer Care Launches Citracal(R) Calcium Plus Heart Health, First-Ever Leading Calcium Supplement to Help Support Bone AND Heart Health
4. Bayer HealthCare Presents Florbetaben Phase II Study Results at World Congress of Neurology
5. Bayer and Onyx Announce Nexavar Data Presentations at 60th American Association for the Study of Liver Diseases Annual Meeting
6. Bayers Novel Anti-Cancer Compound Regorafenib (BAY 73-4506) Showed Stabilization or Regression in 81 Percent of Kidney Cancer Patients
7. Bayer Announces New Data on Oncology Portfolio To Be Presented at the ECCO-ESMO Congress 2009
8. Enrollment Completed in Regeneron and Bayer HealthCare Phase 3 Studies of VEGF Trap-Eye in Neovascular Age-Related Macular Degeneration (Wet AMD)
9. Bayer Announces New Data on Novel Anti-cancer Compound BAY 73-4506
10. Bayer Announces Leukine(R) Data Presentations at 45th American Society of Clinical Oncology (ASCO) Annual Meeting
11. Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... 28, 2014 Concord Medical Services Holdings Limited ... ), a leading specialty hospital management solution provider and ... imaging centers in China , today ... Directors declared a special cash dividend of US$0.30 per ... on the Company,s outstanding ordinary shares. The total expense ...
(Date:7/28/2014)... CHAPEL HILL, N.C. , July 28, 2014 /PRNewswire/ ... results of a clinical trial demonstrating that CXL-1427, a ... was well tolerated in healthy volunteers. The company has ... failure in a Phase IIa clinical trial designed to ... as its dosing levels. The Phase I ...
(Date:7/28/2014)... CARLSBAD, Calif. , July 28, 2014  Isis ... following webcast:What:Isis Pharmaceuticals, Second Quarter 2014 Financial Results and ... / 7:30 a.m. PTWhere: www.isispharm.com How:Live on the ... you are unable to participate during the live event, ... a limited time at www.isispharm.com . ...
Breaking Medicine Technology:Concord Medical Declares Special Dividend 2Cardioxyl Pharmaceuticals Successfully Completes First Clinical Trial For Heart Failure Drug CXL-1427 2Webcast Alert: Isis Pharmaceuticals' Second Quarter 2014 Financial Results Conference Call 2
... PRINCETON, N.J., May 27 Impliant, Inc., a ... today announced,that it has received FDA approval to ... its TOPS(TM) System, a Total Posterior Arthroplasty,device designed ... arthrosis,and spondylolisthesis., (Logo: http://www.newscom.com/cgi-bin/prnh/20080527/NETU060LOGO ), ...
... Only Treatment for Hunter Syndrome Now Approved in 40 Countries ... ... Worldwide, BASINGSTOKE, England and CAMBRIDGE, Massachusetts, May 27, Shire ... that ELAPRASE(R),(idursulfase), a human enzyme replacement therapy for the treatment ...
Cached Medicine Technology:Impliant Restarts Pivotal Clinical Trial for Patented TOPS(TM) Spine System 2Impliant Restarts Pivotal Clinical Trial for Patented TOPS(TM) Spine System 3Shire Announces Approval of ELAPRASE(R) (idursulfase) in Brazil 2Shire Announces Approval of ELAPRASE(R) (idursulfase) in Brazil 3Shire Announces Approval of ELAPRASE(R) (idursulfase) in Brazil 4Shire Announces Approval of ELAPRASE(R) (idursulfase) in Brazil 5
(Date:7/28/2014)... (PRWEB) July 29, 2014 ... in Situ Hybridization, Digital pathology & Workflow, ... Lymphoma, Prostate Cancer, Non Small Cell Lung ... End-Users (Hospitals, Pharmaceutical companies, Research Laboratories, Contract ... (The Americas, Europe, BRIC, Japan & RoW) ...
(Date:7/28/2014)... A lush green lawn offers the perfect setting for ... summer heat, lack of rain, foot traffic, and insects can ... The Grounds Guys recommends these suggestions for nurturing your summer ... week and set the height on the lawn mower about ... from heat and allows roots to retain water and grow ...
(Date:7/28/2014)... MI (PRWEB) July 28, 2014 UHY ... introduces the latest edition of UHY International Business – ... by our members, on the most current business challenges ... the world. Issue 29 covers the following topics:, ... Which industry sectors will thrive over the next five ...
(Date:7/28/2014)... (PRWEB) July 28, 2014 Dawn ... including sales, finance, and music. This experience has ... the direction of psychology. Her professional counseling ( ... and court-ordered treatment for offenders in domestic violence. ... Dawning Phoenix, LLC, she enjoys counseling individuals and ...
(Date:7/28/2014)... A revised version of a surgical procedure to treat ... more than 90 percent of the time in patients ... the MGH Division of Plastic and Reconstructive Surgery report ... the non-endoscopic procedure all of whom had headaches ... symptom relief a year later. The team,s paper ...
Breaking Medicine News(10 mins):Health News:Advanced Cancer Diagnostics Market Worth $3,924.01 Million by 2018 - New Report by MarketsandMarkets 2Health News:Advanced Cancer Diagnostics Market Worth $3,924.01 Million by 2018 - New Report by MarketsandMarkets 3Health News:Advanced Cancer Diagnostics Market Worth $3,924.01 Million by 2018 - New Report by MarketsandMarkets 4Health News:Advanced Cancer Diagnostics Market Worth $3,924.01 Million by 2018 - New Report by MarketsandMarkets 5Health News:Nurturing Lawns in the Summer Heat: The Grounds Guys® Offers Tips on Caring for Lawns This Summer 2Health News:Uhy International Business Issue 29 Now Available 2Health News:Uhy International Business Issue 29 Now Available 3Health News:Dawn M. Echols, M.S., LPC of Dawning Phoenix Speaks at Newly Formed Task Force 2Health News:Non-endoscopic migraine surgery provides significant symptom relief 2
... , RIDGEFIELD, Conn., Sept. 24 Few people ... understanding of what it feels like to live with diabetes every ... That,s about to change. In recognition of World Diabetes Day on ... is challenging people living with diabetes to visually reveal its impact ...
... , , , ... simple task, especially when your child has a chronic health condition ... Frost, has partnered with nonprofit family health organization, Allergy & Asthma ... launch Ti m e 2 Talk Asthma , ...
... (September 24, 2009) Leon Reijmers, PhD, assistant professor ... Boston, is one of 55 recipients of the National ... investigating the way memories are stored in the brain, ... storage. Groups of neurons that participate in long-term ...
... recession, survey finds , THURSDAY, Sept. 24 (HealthDay News) -- ... for many Americans, according to a new survey that found ... a variety of body aches. , An American Pain Foundation ... those who suffered acute back pain or other minor muscle ...
... , NEW YORK, Sept. 24 An Ohio woman, 40-year-old Carolyn ... she,s due to deliver the first week in October is not hers. Several ... to his biological parents. The name of the clinic is not being released ... The AFA is issuing the following statements regarding the matter: , , ...
... , , ROCHESTER, ... Mayo Clinic and Microsoft Corp.,s shared vision to help families take ... to Mayo Clinic Health Manager , a free ... health. People with conditions such as hypertension and high cholesterol will ...
Cached Medicine News:Health News:Video: Making Sense of Diabetes Video Contest Asks 'What Does Diabetes Taste, Smell or Sound Like to You?' 2Health News:Video: Making Sense of Diabetes Video Contest Asks 'What Does Diabetes Taste, Smell or Sound Like to You?' 3Health News:Video: Making Sense of Diabetes Video Contest Asks 'What Does Diabetes Taste, Smell or Sound Like to You?' 4Health News:Parenting Expert and Family Advocate Jo Frost and Allergy & Asthma Network Mothers of Asthmatics (AANMA) Launch Time 2 Talk Asthma 2Health News:Parenting Expert and Family Advocate Jo Frost and Allergy & Asthma Network Mothers of Asthmatics (AANMA) Launch Time 2 Talk Asthma 3Health News:Neuroscientist from Tufts School of Medicine named NIH New Innovator 2Health News:Bad Economy Really Hurts Some Folks 2Health News:The American Fertility Association Responds to Alleged Embryo Mix-Up Case in Ohio 2Health News:The American Fertility Association Responds to Alleged Embryo Mix-Up Case in Ohio 3Health News:Mayo Clinic Health Manager Now Includes Features for People Managing Hypertension and High Cholesterol 2Health News:Mayo Clinic Health Manager Now Includes Features for People Managing Hypertension and High Cholesterol 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: